PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: positive developments in clinical trials and collaborations, but financial challenges persist. The Q&A section highlights promising trial data and competitive positioning, yet management's vague responses and financial strain (net loss increase, cash balance decline) raise concerns. No new partnerships or major strategic shifts were announced, and the lack of guidance on key trials adds uncertainty. Considering these factors, the stock price is likely to remain stable, leading to a neutral prediction.
Key Financial Performance
Net Loss $9.4 million or $0.21 per basic and diluted share for Q2 2025, compared to $8.3 million or $0.23 per share for Q2 2024. The increase in net loss was primarily due to higher net interest expenses, which were partially offset by lower personnel costs.
Research and Development Expenses $4.2 million for Q2 2025, compared to $4.5 million for Q2 2024. The decrease was primarily due to lower personnel costs, which were partially offset by higher manufacturing costs.
General and Administrative Expenses $3.4 million for Q2 2025, compared to $4.2 million for Q2 2024. The decrease was primarily due to lower personnel costs and lower professional fees.
Total Operating Expenses $7.6 million for Q2 2025, compared to $8.7 million for Q2 2024. The decrease was primarily due to lower personnel costs and professional fees.
Net Interest Expenses $1.8 million for Q2 2025, compared to $0.5 million for Q2 2024. The increase was primarily due to debt repayment costs.
Cash Balance $31.9 million as of June 30, 2025, compared to $41.7 million as of December 31, 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VERSATILE-003 Phase III clinical trial: Advancing evaluation of PDS0101 or Versamune HPV in HPV16-positive recurrence and/or metastatic head and neck cancer. The trial includes 350 patients in a 2:1 randomization between treatment and control arms. Median overall survival is the primary endpoint.
VERSATILE-002 trial: Presented positive updated data demonstrating durable clinical benefits of PDS0101 in HPV16-positive head and neck cancer patients. Median overall survival remains steady at 30 months, with no new safety signals.
MC-200710 study: Investigated PDS0101 alone or with pembrolizumab as a neoadjuvant treatment for HPV16-positive oropharyngeal cancer. Results showed clinical activity with 70% response for PDS0101 alone and 100% for the combination.
Colorectal cancer cohort of Phase II trial with PDS01ADC: Met criteria for expansion to Stage 2 following positive Stage 1 results. Observed promising response rate of at least 6 out of 9 confirmed objective responses.
Universal flu vaccine: Preclinical efficacy and immune response data presented at the American Association of Immunologists Immunology 2025 Annual Meeting. Studies funded by NIAID.
HPV16-positive head and neck cancer market: Represents a large and fastest-growing type of head and neck cancer. Over 50% of head and neck cancer cases in the U.S. are HPV16-positive. Projected to become the most prevalent type of head and neck cancer in the U.S. and Europe by mid-2030s.
Financial performance: Net loss of $9.4 million for Q2 2025, compared to $8.3 million in Q2 2024. Cash balance of $31.9 million as of June 30, 2025.
Research and development expenses: $4.2 million for Q2 2025, down from $4.5 million in Q2 2024, primarily due to lower personnel costs.
General and administrative expenses: $3.4 million for Q2 2025, down from $4.2 million in Q2 2024, due to lower personnel costs and professional fees.
Collaborations: Phase II clinical collaborations with National Cancer Institute, MD Anderson Cancer Center, and Mayo Clinic. Preclinical collaboration with NIAID to progress pipeline development while focusing resources on VERSATILE-003 Phase III trial.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The increasing prevalence of HPV16-positive head and neck cancer represents a growing unmet medical need, which could be a challenge if the company fails to effectively address this market opportunity.
Regulatory Hurdles: The company’s forward-looking statements are subject to various risks and uncertainties, including regulatory approvals for its clinical trials and therapies.
Strategic Execution Risks: The company is heavily reliant on the success of its VERSATILE-003 Phase III clinical trial and other pipeline developments. Failure to achieve positive outcomes could significantly impact its strategic objectives.
Financial Risks: The company reported a net loss of $9.4 million for Q2 2025, an increase from the previous year, primarily due to higher net interest expenses. Additionally, the cash balance decreased from $41.7 million to $31.9 million, indicating financial strain.
Competitive Pressures: There are currently no targeted therapies for HPV16-positive cancer, but the company faces potential competition from other emerging therapies in the oncology space.
Supply Chain Disruptions: Higher manufacturing costs were noted, which could indicate potential supply chain challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
VERSATILE-003 Phase III Clinical Trial: The trial is specifically targeting HPV16-positive head and neck cancer. It includes a two-arm design with approximately 350 patients, randomized 2:1. The primary endpoint is median overall survival. The trial is informed by data from the VERSATILE-002 trial, which showed durable clinical responses. No new safety signals have emerged, and the company is confident in the potential of the PDS0101 and pembrolizumab combination to improve outcomes.
Colorectal Cancer Cohort Phase II Trial: The colorectal cancer cohort of the Phase II trial with PDS01ADC met criteria for expansion to Stage 2 following positive Stage 1 results. The trial is expected to complete patient recruitment by Q4 2025. This approach aims to provide effective treatments for metastatic colorectal cancer, which is among the most deadly and difficult-to-treat cancers.
Universal Flu Vaccine Development: Preclinical efficacy and immune response data for a novel universal flu vaccine were presented at the American Association of Immunologists Immunology 2025 Annual Meeting. These studies are funded by the National Institute of Allergy and Infectious Disease Center for influenza vaccine research.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the plan for follow-up on the VERSATILE-002 ASCO data, and when might the final results be reported or published?
A:The VERSATILE-002 trial is still in progress. Once the final patient receives their last treatment, the trial will close. The final data readout, including ORR, PFS, and safety, is expected to be presented or published by the end of this year or early next year, pending review and publication processes.
Q:How is the data dissemination from VERSATILE-002 helping drive enrollment in VERSATILE-003?
A:The data dissemination has been positively received due to the tolerability, ease of administration, and promising median overall survival of the treatment. Investigators and oncologists are encouraged by the results, and many sites from the Phase II study have signed on for VERSATILE-003, which is on schedule for site accrual.
Q:Are there any other large-scale trials with comparable screening criteria to VERSATILE-003?
A:There are fewer competing trials now compared to a year ago. The only major competitor is BioNTech, which is in Phase II moving into Phase III. Their reported median overall survival is not as high as VERSATILE-003's results.
Q:What is the progress of the Mayo Clinic window of opportunity trial, and how does it compare to the KEYNOTE 689 neoadjuvant trial?
A:The Mayo Clinic trial showed responses with and without pembrolizumab in HPV16-positive patients, providing insights for future study designs. KEYNOTE 689 focuses on HPV-negative patients, with only 3% being HPV-positive, making it less relevant for comparison. The Mayo Clinic trial highlights the tolerability and clinical response of PDS0101, even as a monotherapy.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing specific timelines for the Mayo Clinic trial's next steps and provided limited comparative data on competing trials like BioNTech's. Additionally, while emphasizing the tolerability and survival benefits of PDS0101, they did not provide detailed numerical data to substantiate these claims.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASCO Annual
Annual Meeting
HPV oropharyngeal
HPV type
II trial
III trial
Journal
Kirk Chief
Lifesci Advisors
Mayo Clinic
Phase II
Phase III
RECIST version
Results
benefit
cancer HPV
cancer cohort
cohort study
combination pembrolizumab
disease cause
expansion Stage
head cancer
influenza vaccine
oncologist
patient cycle
poster
targeting
test
trial cancer
trial patient
version criterion
PDSB Transcript
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presents a mixed outlook. Positive aspects include new patents for PDS0101 and reduced net loss, suggesting improved financial health. However, significant risks exist, such as the VERSATILE-003 trial amendment and early-stage PDS01ADC trials. The Q&A session highlighted management's evasiveness on certain topics, raising concerns. Overall, the company's financial constraints and pending trial results maintain a neutral sentiment.
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call lacked detailed operational, strategic, and financial updates, which can lead to uncertainty. The amendment to the Phase III trial introduces potential risks and uncertainties. The absence of revenue, margin, and cash flow information, along with unclear management responses in the Q&A, suggests a lack of transparency. These factors are likely to result in a negative market reaction.
PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals financial constraints, with a net loss and declining cash reserves, raising sustainability concerns. The VERSATILE-003 trial pause and lack of clarity on cost savings add uncertainty. The Q&A highlighted management's vague responses on key issues, such as trial adjustments and strategic interests, which may worry investors. Despite some positive developments in trials, market competition and reliance on external collaborations pose risks. Overall, these factors suggest a negative sentiment, likely resulting in a -2% to -8% stock price movement.
PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call summary presents a mixed picture: positive developments in clinical trials and collaborations, but financial challenges persist. The Q&A section highlights promising trial data and competitive positioning, yet management's vague responses and financial strain (net loss increase, cash balance decline) raise concerns. No new partnerships or major strategic shifts were announced, and the lack of guidance on key trials adds uncertainty. Considering these factors, the stock price is likely to remain stable, leading to a neutral prediction.
PDSB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
